Innate Pharma Stock Cash Per Share
| IPHYF Stock | USD 2.90 0.00 0.00% |
Innate Pharma fundamentals help investors to digest information that contributes to Innate Pharma's financial success or failures. It also enables traders to predict the movement of Innate Pink Sheet. The fundamental analysis module provides a way to measure Innate Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innate Pharma pink sheet.
Innate |
Innate Pharma Company Cash Per Share Analysis
Innate Pharma's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Innate Pharma Cash Per Share | 1.54 X |
Most of Innate Pharma's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innate Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Innate Pharma has a Cash Per Share of 1.54 times. This is 64.6% lower than that of the Healthcare sector and 64.43% lower than that of the Biotechnology industry. The cash per share for all United States stocks is 69.26% higher than that of the company.
Innate Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innate Pharma's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innate Pharma could also be used in its relative valuation, which is a method of valuing Innate Pharma by comparing valuation metrics of similar companies.Innate Pharma is currently under evaluation in cash per share category among its peers.
Innate Fundamentals
| Return On Equity | -0.17 | |||
| Return On Asset | -0.043 | |||
| Profit Margin | (0.40) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 91.32 M | |||
| Shares Outstanding | 80.21 M | |||
| Shares Owned By Insiders | 22.50 % | |||
| Shares Owned By Institutions | 10.56 % | |||
| Price To Earning | 40.00 X | |||
| Price To Book | 1.48 X | |||
| Price To Sales | 3.27 X | |||
| Revenue | 12.11 M | |||
| Gross Profit | (22.3 M) | |||
| EBITDA | (36.88 M) | |||
| Net Income | (52.81 M) | |||
| Cash And Equivalents | 123.35 M | |||
| Cash Per Share | 1.54 X | |||
| Total Debt | 13.5 M | |||
| Debt To Equity | 0.37 % | |||
| Current Ratio | 2.34 X | |||
| Book Value Per Share | 1.46 X | |||
| Cash Flow From Operations | (58.46 M) | |||
| Earnings Per Share | (0.69) X | |||
| Number Of Employees | 213 | |||
| Beta | 0.33 | |||
| Market Capitalization | 275.93 M | |||
| Total Asset | 267.5 M | |||
| Z Score | 12.0 | |||
| Net Asset | 267.5 M |
About Innate Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innate Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innate Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innate Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Innate Pink Sheet
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Innate Pink Sheet please use our How to Invest in Innate Pharma guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.